预约演示
更新于：2025-07-15
Mesalamine
美沙拉嗪
更新于：2025-07-15
概要
基本信息
原研机构 |
最高研发阶段批准上市 |
首次获批日期 瑞士 (1984-01-01), |
最高研发阶段(中国)批准上市 |
特殊审评孤儿药 (美国)、孤儿药 (日本) |
登录后查看时间轴
结构/序列
分子式C7H7NO3 |
InChIKeyKBOPZPXVLCULAV-UHFFFAOYSA-N |
CAS号89-57-6 |
关联
344
项与 美沙拉嗪 相关的临床试验NCT06878495
Optimizing IBD Management: A Comparative Study on the Efficacy and Safety of 5-ASA De-escalation in Patients With Ulcerative Colitis and Crohn's Disease on Stable Biologic or Immunomodulator Therapy
NCT06998693
A Single-Center Observational Study on the Impact of Symptom Assessment Timing on the Short-Term Efficacy of 5-ASA Therapy in Patients With Initial-Onset or Relapsed Mild-to-Moderate Active Ulcerative Colitis
NCT06993974
Clinical Study to Evaluate Safety and Efficacy of Nitazoxanide in Patients With Ulcerative Colitis.
100 项与 美沙拉嗪 相关的临床结果
登录后查看更多信息
100 项与 美沙拉嗪 相关的转化医学
登录后查看更多信息
100 项与 美沙拉嗪 相关的专利（医药）
登录后查看更多信息
9,535
项与 美沙拉嗪 相关的文献（医药）2025-12-31ANNALS OF MEDICINE
Sodium butyrate alleviates DSS-induced inflammatory bowel disease by inhibiting ferroptosis and modulating ERK/STAT3 signaling and intestinal flora
Article
作者: Liu, Lulin ; Sun, Suxia ; He, Huaxing ; Chen, Nachuan ; Liu, Yingyin
BACKGROUND:
Inflammatory bowel disease (IBD), encompassing Crohn's disease (CD) and ulcerative colitis (UC), can seriously impact patients' quality of life. Sodium butyrate (NaB), a product of dietary fiber fermentation, has been shown to alleviate IBD symptoms. Some studies have shown that it is related to ferroptosis. However, the precise mechanism linking NaB, IBD, and ferroptosis is not clear.
OBJECTIVE:
This study aimed to demonstrate that NaB suppresses ferroptosis, thereby alleviating inflammatory bowel disease (IBD) through modulation of the extracellular regulated protein kinases/signal transducer and activator of transcription 3 (ERK/STAT3) signaling pathway and intestinal flora.
METHODS:
An IBD model was established using 2.5% (w/v) dextran sulfate sodium (DSS). Mice were orally administered low-dose NaB, high-dose NaB , or 5-aminosalicylic acid (5-ASA). Ferroptosis-related molecules were measured using specific kits, and western blotting (WB) and real-time polymerase chain reaction (RT-qPCR) were used to determine the levels of the target molecules.
RESULTS:
NaB alleviated symptoms in IBD mice, including reduced weight loss, prolonged colon length, reduced disease activity index (DAI), and reduced spleen index and mRNA expression of inflammatory factors. Additionally, NaB reduced the content of Fe2+ and myeloperoxidase (MPO) and increased the content of GSH and the activity of superoxide dismutase (SOD), which reflected NaB-inhibited ferroptosis. Moreover, western blotting showed that NaB enhanced STAT3 and ERK phosphorylation. In addition, NaB regulates the composition and functions of flora related to IBD.
CONCLUSION:
NaB alleviates IBD by inhibiting ferroptosis and modulating ERK/STAT3 signaling and the intestinal flora.
2025-12-01IMMUNOLOGIC RESEARCH
A patient with CVID-enteropathy successfully treated with ustekinumab
Article
作者: Grammatikos, Alexandros ; Marley, Fenella ; Lockett, Melanie ; Gompels, Mark
CVID (common variable immunodeficiency) is associated with a variety of gastrointestinal disorders including those mimicking Crohn's disease and ulcerative colitis. At present there is no clear trial data for the treatment of CVID enteropathy. There are no specific recommendations for treatment; however, it is commonly treated in a similar manner to inflammatory bowel disease, with corticosteroids, 5-aminosalicylates (5-ASA), azathioprine and anti-TNF therapy all being used. We describe the case of a 54-year-old with CVID-enteropathy presenting with diarrhoea and evidence of granulomatous inflammation on colonic biopsies. He was successfully treated with ustekinumab following failure/intolerance of prednisolone, 5-ASA and azathioprine. Features of CVID-enteropathy improved both clinically and histologically, with no evidence of serious treatment-related side effects.
2025-12-01IMMUNOLOGIC RESEARCH
Protective role of ABCC drug subfamily resistance transporters (ABCC1-7) in intestinal inflammation
Article
作者: Miguel-Cruz, Erika ; Yamamoto-Furusho, Jesus K ; Barreto-Zuñiga, Rafel ; Furuzawa-Carballeda, Janette ; Fonseca-Camarillo, Gabriela ; Martínez-Benítez, Braulio
The ABCC subfamily contains thirteen members. Nine of these transporters are called multidrug resistance proteins (MRPs). The MRPs have been associated with developing ulcerative colitis (UC). This study aimed to evaluate the ABCC expression in UC patients and its role in a dextran sulfate sodium (DSS)-induced colitis mice model under 5-aminosalicylates or methylprednisolone treatment and compared with control without inflammation. DSS-induced colitis mice were treated with 5-aminosalicylates (50 mg/kg 24 h) or methylprednisolone (2 mg/kg 24 h). Human rectal biopsies were obtained from UC patients. The abcc-relative mRNA levels and protein expression were determined by RT-PCR and immunohistochemistry. abcc4, abcc5, and abcc6 mRNA levels were significantly increased in DSS-induced colitis compared to the other groups. The 5-aminosalicylate treatment dramatically increased the abcc2 and abcc3 mRNA levels vs. control. Methylprednisolone treatment increased abcc1 vs. DSS-induced colitis and colitis treated with 5-aminosalicylate. Immunohistochemical analysis revealed down-regulation of ABCC1/ABCC2/ABCC5/ABCC7 in mice colitis vs. control. Treatment with 5-aminosalicylate restored ABCC5 levels, while methylprednisolone restored ABCC2/ABCC5/ABCC7 in colitis mice at similar control levels. Relative mRNA levels of mrp1-5 were increased in active UC patients vs. control. ABCC2/ABCC4/ABCC7 were conspicuously expressed in the mucosa of 5-aminosalicylate and/or methylprednisolone-treated UC patients, while ABCC2/ABCC4/ABCC5/ABCC7 in submucosa, ABCC1/ABCC5/ABCC7 in muscular, and ABCC1/ABCC4/ABCC5/ABCC7 in serosa were expressed vs. controls. This is the first report about the differential up-regulation of the ABCC subfamily gene and protein expression in DSS-induced colitis under aminosalicylates or methylprednisolone treatment.
100 项与 美沙拉嗪 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 活动性中度溃疡性结肠炎 | 加拿大 | 2017-06-30 | |
| 溃疡性直肠炎 | 美国 | 2001-01-05 | |
| 克罗恩病 | 日本 | 1996-04-16 | |
| 克罗恩病 | 日本 | 1996-04-16 | |
| 胃肠道疾病 | 美国 | 1993-05-10 | |
| 直肠炎 | 美国 | 1987-12-24 | |
| 直肠结肠炎 | 美国 | 1987-12-24 | |
| 溃疡性结肠炎 | 瑞士 | 1984-01-01 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 淋巴细胞性结肠炎 | 临床3期 | 德国 | 2010-05-01 | |
| 食管憩室病 | 临床3期 | 美国 | 2007-12-06 | |
| 食管憩室病 | 临床3期 | 巴西 | 2007-12-06 | |
| 食管憩室病 | 临床3期 | 加拿大 | 2007-12-06 | |
| 食管憩室病 | 临床3期 | 芬兰 | 2007-12-06 | |
| 食管憩室病 | 临床3期 | 德国 | 2007-12-06 | |
| 食管憩室病 | 临床3期 | 匈牙利 | 2007-12-06 | |
| 食管憩室病 | 临床3期 | 意大利 | 2007-12-06 | |
| 食管憩室病 | 临床3期 | 荷兰 | 2007-12-06 | |
| 食管憩室病 | 临床3期 | 罗马尼亚 | 2007-12-06 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
NEWS 人工标引  | N/A | 198 | 壓鑰製壓艱窪遞醖鬱餘(鏇壓糧觸窪淵糧鹹選遞) = 鏇窪膚獵顧餘廠壓醖築 齋網艱選衊積構遞鹹鬱 (襯鹹廠遞糧選鏇網夢衊 ) 更多 | 积极 | 2025-03-05 | ||
REALASA (NEWS) 人工标引 | N/A | 溃疡性结肠炎 一线 | - | 襯鹹製窪鏇築糧衊餘獵(鑰範憲衊窪遞糧襯鹽繭) = 约50%的患者在182天时对初始5-ASA治疗保持依从性，但这一比例在730天时降至30%。 鏇積壓齋憲淵範製鹹觸 (鏇憲獵夢襯窪鹹鹹願憲 ) | 积极 | 2025-02-26 | |
NEWS 人工标引 | N/A | - | 5-ASA 低剂量（<2 g/天） | 蓋鑰鬱簾獵廠顧願簾艱(糧願積夢鬱鏇網遞窪遞) = 齋鹽繭餘遞遞築願窪繭 獵廠醖糧獵鹽膚願築獵 (顧糧衊積醖顧願壓鏇憲 ) | 积极 | 2025-02-26 | |
5-ASA 低剂量联合治疗 | 蓋鑰鬱簾獵廠顧願簾艱(糧願積夢鬱鏇網遞窪遞) = 繭醖醖窪壓築積鑰選鬱 獵廠醖糧獵鹽膚願築獵 (顧糧衊積醖顧願壓鏇憲 ) | ||||||
N/A | - | Mesalazine (Asacol) | 壓餘鹽餘憲遞鏇艱壓糧(繭簾襯憲觸淵製夢憲淵) = 鹹網艱窪築壓糧簾襯積 憲窪淵窪網淵鹽淵鏇遞 (顧鑰襯觸積夢鏇膚夢製 ) 更多 | - | 2024-10-13 | ||
Ozanimod (Zeposia) | 壓餘鹽餘憲遞鏇艱壓糧(繭簾襯憲觸淵製夢憲淵) = 齋憲襯鹽觸蓋窪鏇窪鏇 憲窪淵窪網淵鹽淵鏇遞 (顧鑰襯觸積夢鏇膚夢製 ) 更多 | ||||||
临床3期 | 溃疡性结肠炎 维持 | 107 | Low-dose multimatrix mesalamine (900-2400 mg) | 膚衊願顧築艱簾獵衊蓋(製衊艱膚願廠廠簾廠艱) = Overall, 246 treatment-emergent adverse events (TEAEs) were reported in 73 patients (69.5%); 23 TEAEs in 14 patients (13.3%) were considered related to the study drug. No treatment-related deaths were reported. 齋蓋淵範廠網壓窪獵積 (壓齋顧窪蓋醖餘顧範襯 ) 更多 | 积极 | 2023-11-01 | |
High-dose multimatrix mesalamine (1800-4800 mg) | |||||||
N/A | - | pH-dependant Mesalazine (5-ASA) Formulation 1 | 願簾獵窪艱遞積夢範願(醖簾廠鑰艱構夢顧齋蓋) = 膚鏇憲齋構鹽遞襯積鏇 壓獵糧蓋積積蓋壓艱範 (願壓簾鏇獵築蓋願築壓 ) | - | 2023-05-09 | ||
pH-dependant Mesalazine (5-ASA) Formulation 2 | 願簾獵窪艱遞積夢範願(醖簾廠鑰艱構夢顧齋蓋) = 築顧構鑰鑰選築觸壓選 壓獵糧蓋積積蓋壓艱範 (願壓簾鏇獵築蓋願築壓 ) | ||||||
N/A | 溃疡性结肠炎 ESR | MPO | PR3 antibodies | - | 網繭鏇襯積鑰醖築衊夢(窪襯築製願鏇襯襯築艱) = Mesalamine induced FSGS must be considered in the differential early on presentation of a patient with nephrotic syndrome to ensure adequate and appropriate treatment to preserve kidney function 憲獵簾製顧鹹齋網鹽選 (構遞觸鏇鹹顧鑰築鏇壓 ) | 不佳 | 2022-11-05 | ||
N/A | 溃疡性结肠炎 维持 | 177 | 5-aminosalicyclic acid (5-ASA) | 蓋積網糧積蓋製鏇蓋範(鏇築顧遞鹽夢鏇醖獵餘) = 鏇構遞廠觸鏇襯醖鑰膚 鬱壓醖壓範艱齋願鹽窪 (窪憲鬱鏇範選衊獵壓觸 ) | 积极 | 2022-10-09 | |
Placebo | 蓋積網糧積蓋製鏇蓋範(鏇築顧遞鹽夢鏇醖獵餘) = 齋簾顧顧積壓顧艱餘夢 鬱壓醖壓範艱齋願鹽窪 (窪憲鬱鏇範選衊獵壓觸 ) | ||||||
N/A | - | (Control group) | 選獵築憲鑰網鹽襯壓範(簾鹽獵蓋襯衊鑰積淵觸) = 遞構糧憲鏇鑰衊鹽積顧 觸積構廠艱構獵築網遞 (選鹽範簾觸艱淵蓋築窪 ) 更多 | - | 2022-05-21 | ||
N/A | 151 | 淵膚蓋餘選淵糧鬱壓範(窪繭鑰膚鬱獵憲醖淵蓋) = 齋膚繭醖鏇構願餘廠遞 蓋糧醖鏇蓋餘觸鑰獵築 (鹹築餘鹽範淵遞鏇齋繭 ) 更多 | 积极 | 2022-03-19 | |||
Mesalazine 2-<4 g/day | 繭遞製衊構鏇鹹膚糧範(衊製窪憲鹽艱遞齋構齋) = 壓製淵願觸蓋衊範廠憲 顧鹹窪網糧繭範鏇獵膚 (鏇憲觸構艱遞淵壓艱遞 ) |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用